ReviewMicroorganisms2021
Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Molecular and Functional Interactions Between Cisplatin and Nicotinamide: A Combined Computational, Spectroscopic, and Biological Study.International journal of molecular sciences · 2026Article
- Article
- Article
- No evidence of multidrug-resistantMicrobiology spectrum · 2025Observational
- New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2025Review
- Rapid screening for carbapenemase-producing carbapenem-resistantMicrobiology spectrum · 2025Article
- Prevalence of New Delhi Metallo-β-lactamase (blaMolecular biology reports · 2025Article
- Performance comparison of BD Phoenix CPO detect panel with Cepheid Xpert Carba-R assay for the detection of carbapenemase-producing Klebsiella pneumoniae isolates.BMC microbiology · 2024Article
- Clinical Risk Factors and Microbiological and Intestinal Characteristics of Carbapenemase-ProducingMicrobiology spectrum · 2022Article
- Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Carbapenem antibiotic stress increases blaJournal of clinical laboratory analysis · 2022Article
- Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Detection of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Emerging Carbapenem-ResistantInfection and drug resistance · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.